{"title":"Association of blood biomarkers with p53 gene expression in male infertility.","authors":"Aswathi Ramachandran Krishnakumary, Natrajan Muninathan, Arumugam Suresh, Mohanalakshmi Parthasarathy, Dinesh Roy Divakaran","doi":"10.1515/hmbci-2026-0003","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To investigate the association between p53 gene expression, prostate-specific antigen (PSA), and oxidative stress markers (sialic acid and vitamin C) in infertile men.</p><p><strong>Methods: </strong>This case-control study involved 150 infertile men and 150 fertile controls from Kerala, India. Serum sialic acid, PSA, and vitamin C were measured by ELISA, and p53 expression was quantified by real-time PCR (2<sup>-ΔΔCt</sup> method). Non-parametric tests, correlation analyses, regression models, and ROC curves were used to assess associations, predictive value, and diagnostic performance.</p><p><strong>Results: </strong>Infertile men showed significantly lower serum sialic acid and vitamin C levels and higher PSA concentrations and p53 gene expression than fertile controls (all p<0.05). p53 expression was significantly associated with PSA, sialic acid, and vitamin C in infertile men. Although no biomarker independently predicted infertility in logistic regression, robust linear regression identified vitamin C as a strong negative predictor and PSA as a positive predictor of p53 expression. ROC analysis revealed moderate discriminative ability for vitamin C, PSA, and sialic acid, while p53 expression alone showed limited diagnostic accuracy.</p><p><strong>Conclusions: </strong>The concurrent elevation of <i>p53</i> expression, increased PSA levels, and antioxidant depletion in infertile men reflects activation of cancer-related cellular stress and genomic surveillance pathways rather than evidence of malignancy.</p>","PeriodicalId":13224,"journal":{"name":"Hormone Molecular Biology and Clinical Investigation","volume":" ","pages":""},"PeriodicalIF":1.3000,"publicationDate":"2026-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hormone Molecular Biology and Clinical Investigation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/hmbci-2026-0003","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: To investigate the association between p53 gene expression, prostate-specific antigen (PSA), and oxidative stress markers (sialic acid and vitamin C) in infertile men.
Methods: This case-control study involved 150 infertile men and 150 fertile controls from Kerala, India. Serum sialic acid, PSA, and vitamin C were measured by ELISA, and p53 expression was quantified by real-time PCR (2-ΔΔCt method). Non-parametric tests, correlation analyses, regression models, and ROC curves were used to assess associations, predictive value, and diagnostic performance.
Results: Infertile men showed significantly lower serum sialic acid and vitamin C levels and higher PSA concentrations and p53 gene expression than fertile controls (all p<0.05). p53 expression was significantly associated with PSA, sialic acid, and vitamin C in infertile men. Although no biomarker independently predicted infertility in logistic regression, robust linear regression identified vitamin C as a strong negative predictor and PSA as a positive predictor of p53 expression. ROC analysis revealed moderate discriminative ability for vitamin C, PSA, and sialic acid, while p53 expression alone showed limited diagnostic accuracy.
Conclusions: The concurrent elevation of p53 expression, increased PSA levels, and antioxidant depletion in infertile men reflects activation of cancer-related cellular stress and genomic surveillance pathways rather than evidence of malignancy.
期刊介绍:
Hormone Molecular Biology and Clinical Investigation (HMBCI) is dedicated to the provision of basic data on molecular aspects of hormones in physiology and pathophysiology. The journal covers the treatment of major diseases, such as endocrine cancers (breast, prostate, endometrium, ovary), renal and lymphoid carcinoma, hypertension, cardiovascular systems, osteoporosis, hormone deficiency in menopause and andropause, obesity, diabetes, brain and related diseases, metabolic syndrome, sexual dysfunction, fetal and pregnancy diseases, as well as the treatment of dysfunctions and deficiencies. HMBCI covers new data on the different steps and factors involved in the mechanism of hormone action. It will equally examine the relation of hormones with the immune system and its environment, as well as new developments in hormone measurements. HMBCI is a blind peer reviewed journal and publishes in English: Original articles, Reviews, Mini Reviews, Short Communications, Case Reports, Letters to the Editor and Opinion papers. Ahead-of-print publishing ensures faster processing of fully proof-read, DOI-citable articles.